Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Assmus, Frauke, Driouich, Jean-Sélim, Abdelnabi, Rana, Vangeel, Laura, Touret, Franck, Adehin, Ayorinde, Chotsiri, Palang, Cochin, Maxime, Foo, Caroline S., Jochmans, Dirk, Kim, Seungtaek, Luciani, Léa, Moureau, Grégory, Park, Soonju, Pétit, Paul-Rémi, Shum, David, Wattanakul, Thanaporn, Weynand, Birgit, Fraisse, Laurent, Ioset, Jean-Robert, Mowbray, Charles E., Owen, Andrew, Hoglund, Richard M., Tarning, Joel, de Lamballerie, Xavier, Nougairède, Antoine, Neyts, Johan, Sjö, Peter, Escudié, Fanny, Scandale, Ivan, Chatelain, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460261/
https://www.ncbi.nlm.nih.gov/pubmed/36014057
http://dx.doi.org/10.3390/microorganisms10081639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460261/
https://www.ncbi.nlm.nih.gov/pubmed/36014057
http://dx.doi.org/10.3390/microorganisms10081639

Ejemplares similares